Unveiling the
Link: HLA-B27 Genetic Marker and Interleukin Levels in Psoriatic Arthritis Patients
Jayaprakash T., Leela K.V., Rahul H.L. and Subramaniyan K.
Res. J. Biotech.; Vol. 20(12); 130-137;
doi: https://doi.org/10.25303/2012rjbt1300137; (2025)
Abstract
This study aimed to examine the occurrence of Human leukocyte antigen-B27 (HLA-B27)
and its subtypes, alongside the levels of the inflammatory markers Interleukin-17
and Interleukin-23 in individuals diagnosed with psoriatic arthritis (PsA), a multifaceted,
polygenic disorder strongly influenced by genetic factors. An observational cross-sectional
study was carried out that included patients who satisfied the CASPAR criteria for
Psoriatic arthritis. This study revealed a male predominance among PsA patients
and an association between HLA-B27 positivity and an earlier age of onset.
Notably, theHLA-B27 subtypes B27:05, B27:04 and HLA-B27:02, B27:07 were not detected
in any HLA-B27 positive Psoriatic arthritis patients in our study. Additionally,
elevated levels of Interleukin-17 and Interleukin-23 were observed, particularly
in Human leukocyte antigen-B27 positive PsA patients.
